KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Acquisitions & Divestments (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Change in Acquisitions & Divestments for 13 consecutive years, with $273.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 225.54% to $273.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $722.2 million, a 82.58% increase, with the full-year FY2025 number at $722.2 million, up 82.58% from a year prior.
  • Change in Acquisitions & Divestments was $273.4 million for Q4 2025 at Halozyme Therapeutics, up from $209.6 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $590.0 million in Q2 2022 to a low of $15.6 million in Q4 2023.
  • A 5-year average of $122.3 million and a median of $76.9 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 667.59% in 2022, then tumbled 90.95% in 2023.
  • Halozyme Therapeutics' Change in Acquisitions & Divestments stood at $69.8 million in 2021, then plummeted by 71.18% to $20.1 million in 2022, then fell by 22.52% to $15.6 million in 2023, then soared by 438.34% to $84.0 million in 2024, then soared by 225.54% to $273.4 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Change in Acquisitions & Divestments are $273.4 million (Q4 2025), $209.6 million (Q3 2025), and $189.1 million (Q2 2025).